CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-07-01 | Sinha Vikas Director | Grant or award · Stock Option (Right to Buy) | +54,600 | 54,600 | ||
| 2022-07-01 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award | +14,000 | 403,011 | ||
| 2022-07-01 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2022-07-01 | Atillasoy Ercem | Grant or award | +14,000 | 135,563 | ||
| 2022-07-01 | Atillasoy Ercem | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2022-07-01 | Brainard Diana Chief Executive Officer | Grant or award | +48,125 | 542,112 | ||
| 2022-07-01 | Brainard Diana Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +89,375 | 89,375 | ||
| 2022-06-03 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −515 | $3.63 | $2K | 389,011 |
| 2022-06-03 | Hallal David Director | Sale | −65,725 | $3.67 | $241K | 2,077,889 |
| 2022-05-18 | Brainard Diana Chief Executive Officer | Sale | −29,135 | $4.33 | $126K | 492,165 |
| 2022-05-17 | Bornstein Jeffrey S Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | Jovan-Embiricos Morana Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | Brenner Malcolm Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | GADICKE ANSBERT Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | Vera Juan Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2022-05-17 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −15,262 | $4.40 | $67K | 389,526 |
| 2022-04-26 | Bornstein Jeffrey S Director | Purchase | +5,000 | $4.64 | $23K | 40,197 |
| 2022-04-21 | Hallal David Director | Sale | −4,227 | $5.87 | $25K | 2,143,614 |
Page 14 of 27 · 527 trades